House dust mite allergen-specific adaptive immune response

The house dust mite (HDM) allergen-specific adaptive immune response is a complex physiological cascade initiated by the inhalation or contact with proteins from Dermatophagoides species, such as Der p 1 and Der p 2. This response begins when allergens bypass the epithelial barrier and are captured by dendritic cells, which process and present allergen-derived peptides to naive CD4+ T cells in the lymph nodes (Gregory and Lloyd, 2011). These T cells differentiate into Th2 cells, which secrete a signature profile of cytokines including IL-4, IL-5, and IL-13, driving B-cell class switching to IgE and the recruitment of eosinophils to the site of exposure (Hammad and Lambrecht, 2015). The resulting IgE sensitizes mast cells and basophils, leading to the classic symptoms of allergic asthma, rhinitis, and dermatitis upon re-exposure. While various drugs target specific molecular components of this pathway—such as Omalizumab targeting IgE or Dupilumab targeting the IL-4 receptor—the response itself is a multi-step biological process rather than a single druggable target (Galli et al., 2008). Consequently, it is classified as a pathway or physiological response in the context of drug development and immunology.

Other names

HDM-induced adaptive immunityHouse dust mite allergy pathwayHDM-specific Th2 responseDermatophagoides-specific immune response

Therapeutic strategies involve neutralizing IgE to prevent mast cell degranulation, blocking Th2 cytokines (IL-4, IL-5, IL-13) or their receptors to reduce eosinophilic inflammation, inhibiting upstream alarmins like TSLP, or utilizing allergen-specific immunotherapy (AIT) to induce peripheral T-cell tolerance and increase regulatory T-cell (Treg) activity (Calderón et al., 2015; Galli et al., 2008).